Thermostable Biopharmaceuticals For Delivery Without Reconstitution

Size: px
Start display at page:

Download "Thermostable Biopharmaceuticals For Delivery Without Reconstitution"

Transcription

1 Thermostable Biopharmaceuticals For Delivery Without Reconstitution V. Bronshtein Supported by NIH Grants U01AI070350, 5R44AI080035, 5R21AI094508, and CDC Contract Number

2 Bottlenecks for Effective Applications of Vaccines and Other Fragile Biopharmaceuticals A need for maintaining a cold chain for vaccine storage and distribution. A need for reconstitution of vaccines with sterile water or aqueous solutions. A need for a conventional needle-based parental vaccine delivery. A need for using trained medical personal and special facilities for parental vaccination.

3 Could Biopharmaceuticals Be Delivered Without Reconstitution Using Methods Developed for Conventional Pharmaceuticals? Many conventional pharmaceuticals could be stored at ambient temperatures (AT) and delivered via oral (intestinal, sublingual, and buccal), transdermal, respiratory, vaginal, and anal delivery routes without reconstitution with water before the delivery, avoiding painful parenteral delivery and help of medical personal. Pharmaceutical industry had developed sophisticated methods and tools for production, tablets, dissolvable films, patches, suppositories, ointment, creams, and capsules (including enteric coated capsules for intestinal delivery) that are used for needle free delivery of the pharmaceuticals. The question is what is stopping us from doing the same for biopharmaceuticals?

4 Industry Problem: Most of Bio-pharmaceuticals (i.e. vaccines) currently produced using freeze-drying (FD) or spray-drying (SD) are not thermostable. Still, despite major limitations and shortcomings, freeze-drying and spraydrying remain the primary methods for stabilization of vaccines and other biopharmaceuticals in the dry state. Procedures that are currently used for preparation tablets, dissolvable films, patches, suppositories, ointment, etc. often include usage of materials and substances that are harmful for dry preserved biopharmaceuticals. In addition, they may include short term application of high temperatures, shear stresses, and other harmful conditions, destroying biologicals.

5 UST Solution for Production of Micronized Thermostable Biopharmaceuticals: First: Thermostabilization using PBV technology. Second: Micronization of the thermostable product using jet milling.

6 History and Development of Foam Drying and Preservation by Vaporization (PBV) Annear preserved bacteria by foaming a syrup under vacuum. The syrup was obtained by evaporation. No freezing of the material was involved. Drawbacks: The process is applicable only to small volumes (several ml or less) of material. Syrup often does not foam Roser and Gibbon proposed to use the same (Annear) process for other biologics Bronshtein proposed using Preservation by Foam Formation (PFF) as an alternative to freeze-drying (Pharmaceutical Technology 28, 86-92, 2004). He suggested obtaining the syrup by boiling in order to make the process scalable. Drawbacks: Splashing, difficult to control and reproduce PFF process Bronshtein proposed Preservation by Vaporization (PBV), during which a partially frozen material sublimates, boils and evaporates simultaneously (PCT Patent Application WO A). It is scalable, easy to control and reproduce, and has minimum splashing...

7 Outside Research Supports the Superior Thermostability Offered by Foam Drying Monoclonal antibodies: Abdul-Fattah AM et al J Pharm Sci. 96 (8): Parainfluenza strain vaccine: Abdul-Fattah AM et al Pharm Res. 24 (4): Human serum albumin: Hajare AA et al Curr Drug Deliv. Francisella tularensis live vaccine: Ohtake S et al J Pharm Sci. 8 (6): Salmonella typhi live vaccine: Ohtake S et al Vaccine. 29 (15): LaSota virus: Pisal S et al AAPS PharmSciTech. 7 (3): 60.

8 Benefits of PBV Technology: Higher activity titer after drying and thermostability during subsequent storage (increased shelf-life). Eliminates the need of using a cold chain. Allows subsequent particle size reduction (micronization). Allows drying of vaccines encapsulated in gel microparticles for better intestinal delivery avoiding the need of reconstitution with water. Allows short-term (several hours) stability at 60 C to 90 C that could be used for encapsulation of dry powders in dissolvable polymeric films for buccal and transdermal delivery avoiding a need of reconstitution with water. Allows scalable continuous load barrier drying. Eliminate drawbacks of PFF.

9 Formulation of Patches and Quick-Dissolve Films for Delivery of Biopharmaceuticals 1. To make patches for transdermal delivery and quick-dissolve films for buccal, sublingual, and vaginal delivery, we cast liquid mixtures comprising water-soluble polymer, plasticizer, and sugar glass particles with biopharmaceuticals preserved inside the sugar glass into a mold. 2. The liquid mixtures can be prepared by melting polymer at elevated temperatures or by dissolving polymers in anhydrous solvents that do not dissolve the sugar glass. Sugar glass particles should be phase separated from the polymer in both solid and liquid state before casting. In addition, incorporating sugar glass particles inside a water-soluble polymer matrix should be performed in low humidity environment to avoid decrease of the sugar glass transition temperature. 3. Casting can be achieved by solidifying the melted polymers or polymer solutions in a mold by cooling, by evaporation of the solvent, fusion of polymeric powders by application of mechanical stresses, or by polymerizing monomers using irradiation or application of other physical and chemical factors. 4. To ensure that biopharmaceuticals can be placed inside melted polymer matrixes, we make preserved biopharmaceuticals thermostable for the short-term (i.e. an hour at 70 C to 90 C). For casting processes that include solvent evaporation we select solvents that are phase separated from sugar glass and do not harm biopharmaceuticals preserved inside the glass.

10 Quick-Dissolve Film Produced by Solvent Casting Method (In Collaboration with Dr. Lisa Rohan s Lab at MWRI) Magee Womens Research Institute

11 Examples of PBV Formulations for Proteins:

12 hbche Activity (%) Stability of Thermostabilized Butyrylcholiesterase (hbche) at High Temperatures C 37 C Room Temperature Time of Storage (month)

13 PA83 PBV Formulations: Immunogenicity

14 Immunogenicity of PA83 Foam-Dried Formulations P4 and P5 Experimental Design: Primary Immunization Secondary immunization Bleed 3 weeks 3 weeks Pre-bleed Day 21 Day 42 Day 70 Groups Balb/c 6wks Vaccine candidate Formulation Form Route Alhydrogel Dose at days 0 and 21 (µg/dose) 1 6 PA83 P4A Foam IM 0.3% PA83 P4B Foam IM 0.3% PA83 P5A Foam IM 0.3% PA83 P5B Foam IM 0.3% Saline Saline N/A IM 0.3% 7.5

15 Anthrax Lethal Toxin Neutralizing Antibody (TNA) Titers 7.5 (5) µg 0.3% Alhydrogel Formulation 4A 4B 5A 5B PA83 Saline Saline only GMT ED 50 ± SE Day 20 15±3 13±1 17±4 20±4 21±3 19±2 Day ± ± ± ± ± ± 0 Day ± ± ± ± ± ± 1 % Responders Day 42 67% 50% 100% 50% 50% 0% % Responders Day 70 67% 50% 100% 67% 67% 0% Data are represented at geometric mean effective dose 50 (ED 50 ) titers (GMT) % responders are determined when the GMT of a samples is to the GMT of a PA mab Results show that formulation P5A generated the highest TNA titers with 100% of mice responding after the booster dose. The response decreased slightly by study day 70, but remained significantly higher than the rest of the groups. The other foam dried formulations behaved similarly to the PA83 is saline.

16 PA83 Foam Dried Formulations: Stability at 37ºC

17 Foam dried Formulations Stability at 37 C: SDS PAGE and Western Blot Data

18 Summary and Conclusions SDS PAGE and Western blot data suggest that foam dried PA83 5A formulation is stable for 6 months at 37 C. Reconstituted PA83 after 6 month storage at 37 C does not lose its potential to bind to Alhydrogel adjuvant, as determined by the absence of the target molecule from the supernatant after Alhydrogel removal by centrifugation.

19 Examples of PBV Formulations for Viral Vaccines:

20 Thermostability and Activity of Live ERA Rabies Vaccine after PBV Drying and Encapsulation in Polyethylene Glycol (PEG) MW 35, Rabies vaccine activity titer (log FFU/ml) Activity be fore drying Activity afte r drying Activity after 3 hours at 80 C Activity after encapsulation in PEG at 80 C Activity Activity ater 23 ater months 23 m at onths RT at RT Activity after 1 m onth at 37 C 0

21 Stability of PBV Preserved YF-VAX Vaccine17D at 37 C. Activity of YF-17D vaccine (log 10 PFU/0.5ml) Form. that do not contain MAG (Metyl Glycoside) Control stored Control at -80 C Stored at -80 C Form. containing MAG Activity of Freeze-Dried YF-VAX 17D Activity Manufactured of freeze-dried by Sanofi YF-VAX Pasteur, 17D vaccine Inc. manufactured by Sanofi Pasteur Inc. Titer After 15 Months at RT: 4.55±0.23 (log 10 PFU/0.5ml) Formulations Including MAG Days of storage at 37 C Formulations Not Including MAG

22 Particle Size Distribution After Jet Milling of PBV Preserved YF-VAX 17D 14 Statistics Graph (65 measurements) 10µm Volume (%) Mean with +/- 1 Standard deviation error bar Particle Size (µm)

23 Stability of PBV Preserved MVA at 37 C 8 Activity Titer (Log 10 PFU/ml) 7 6 Formulation 1 Formulation 2 (Includes MAG) Formulation 3 (Includes MAG) Formulation 4 Stability of freeze-dried MVA vaccine (Baxter) Time of Storage at 37 C (Weeks)

24 PBV Preserved YF-VAX 17D Can be Micronized Using Jet Milling with Minimum Activity Loss 7 6 Titer (log 10 PFU/0.5ml) Titer of Preservation Mixture Before Drying Titer After Drying Titer Aftert Jet Milling (Micronization) 0

25 Stability of PBV Preserved Measles Vaccine at 37 C (Evaluated in Dr. Rota s Laboratory at CDC) % of Vaccine Activity Before Drying Measured in TCID50/ml Time of storage at 37 C (Months)

26 Examples of PBV Formulations for Bacteria:

27 Survival of PBV bacteria (10 8 CFU/ml) at 37 C and 70 C Treatment Activity of L. rhamnosus Activity of L. jensenii Activity of L. crispatus Before drying Form. 1 Form. 2 Form ± ±15 118±12 137±12 119±14 95±28 94±9 93±14 After drying Form. 1 Form. 2 Form. 3 After 1 hour at 70ºC Form. 1 Form. 2 Form. 3 After 3 months at 37ºC Form. 1 Form. 2 Form. 3 After 6 months at 37ºC Form. 1 Form. 2 Form. 3 After 11 months at 37ºC Form. 1 Form. 2 Form. 3 After 11 months at RT Form. 1 Form. 2 Form. 3 93±1.5 77±8 103±14 81±6 56±21 109±3 78±6 69±3 15±6 49±7 31±8 3.4±0.6 76±7 2.4±1.7 1± ±10 100±16 68±6 110±15 106±12 126±22 101±8 85±11 104±19 116±20 49±29 54±9 31±7 47±3 23±4 42±3 31±3 4.5±1 86±15 86±10 94±16 70±12 65±13 67±8 67±8 50±3 56±9 52±9 37±6 53±15 52±12 25±3 40±7 33± ±19 36±11 2.5±2.5

28 L. Rhamnosus PBV Formulation Micronized Using Jet Milling 200 μm 100 μm

29 Quick-Dissolve Film Produced by Solvent Casting Method (In Collaboration with Dr. Lisa Rohan s Lab at MWRI) Magee Womens Research Institute

30 Acknowledgements We would like to thank our collaborators from CDC and University of Pittsburg who allowed to share with you some results of our work.

At LATITUDE, we only do one thing, and we do it very well.

At LATITUDE, we only do one thing, and we do it very well. Formulation Experts for Insoluble Compounds At LATITUDE, we only do one thing, and we do it very well. LATITUDE Pharmaceuticals Inc. has been tackling the most difficult drug formulation challenges for

More information

EVALUATION OF NEW FILM COATING PROCESSES AND MATERIALS

EVALUATION OF NEW FILM COATING PROCESSES AND MATERIALS EVALUATION OF NEW FILM COATING PROCESSES AND MATERIALS Inaugural-Dissertation zur Erlangung der Doktorwurde im Fachbereich Biologie, Chemie, Pharmazie der Freien Universitat Berlin vorgelegt von NANTHARAT

More information

Development of Vaxfectin -formulated HSV-2 Plasmid DNA Vaccines for Prophylactic and Therapeutic Applications

Development of Vaxfectin -formulated HSV-2 Plasmid DNA Vaccines for Prophylactic and Therapeutic Applications Development of Vaxfectin -formulated HSV-2 Plasmid DNA Vaccines for Prophylactic and Therapeutic Applications Sean M. Sullivan, Ph.D. Executive Director Pharmaceutical Sciences 14 July 2011 - DNA Vaccines

More information

Foam Drying and Foam Freeze Drying Process Loss and Stability

Foam Drying and Foam Freeze Drying Process Loss and Stability Foam Drying and Foam Freeze Drying Process Loss and Stability Reinhard Vehring Associate Director, Solid Dosage Forms MedImmune Inc. 319 North Bernardo Ave, Mountain View, CA 94043 Outline Introduction

More information

High-Concentration Monoclonal Antibody Powder Suspension in Non-aqueous Vehicle for Subcutaneous Injection

High-Concentration Monoclonal Antibody Powder Suspension in Non-aqueous Vehicle for Subcutaneous Injection Slide 1 High-Concentration Monoclonal Antibody Powder Suspension in Non-aqueous Vehicle for Subcutaneous Injection Mayumi Bowen Pharmaceutical Processing & Technology Development Genentech, Inc AAPS Annual

More information

Balancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL

Balancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL Balancing the time, cost and risk of drug development Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL Communicating vessels Risk Time Cost Communicating vessels

More information

Howida Kamal, Ph.D. Ass. Prof. of Pharmaceutics, Cairo University

Howida Kamal, Ph.D. Ass. Prof. of Pharmaceutics, Cairo University Howida Kamal, Ph.D Ass. Prof. of Pharmaceutics, Cairo University Dosage forms Sterile Free from all forms of microbial life (vegetative & sporing) Free from pathogens Non-sterile Extent of total bioburden

More information

Institute of Pharmaceutical Technololgy and Biopharmacy University of Pécs

Institute of Pharmaceutical Technololgy and Biopharmacy University of Pécs Institute of Pharmaceutical Technololgy and Biopharmacy University of Pécs 1 Faculty of Pharmacy H-7624 Pécs, Rókus str.2. 2 Faculty of Pharmacy Department of Pharmacetical Biotechnology Department of

More information

Performance Testing of Novel Dosage Forms

Performance Testing of Novel Dosage Forms RQA Ireland Regional Forum - Athlone, May 2016 Quality Considerations Pharma and Biopharma Performance Testing of Novel Dosage Forms Terry Way BPharm MAPS Dissolution Science Consultant Glasside Technologies

More information

Young Innovators 2011

Young Innovators 2011 Young Innovators 2011 Formulation of Novel Particulate Breast Cancer Vaccines using Spray Drying and In Vivo Evaluation of Vaccine Efficacy 2011 AAPS Graduate Student Symposium Awards in Biotechnology

More information

Issues Related to the Formulation and Delivery of Pharmaceutical Proteins

Issues Related to the Formulation and Delivery of Pharmaceutical Proteins Issues Related to the Formulation and Delivery of Pharmaceutical Proteins Pretoria16 August Prof. dr. Daan J.A. Crommelin Dept. Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, UIPS Scientific

More information

The science of transforming an Active Pharmaceutical Ingredient (API) into a Drug Product (DP) in a specific dosage form.

The science of transforming an Active Pharmaceutical Ingredient (API) into a Drug Product (DP) in a specific dosage form. The science of transforming an Active Pharmaceutical Ingredient (API) into a Drug Product (DP) in a specific dosage form. Three major needs that the formulation into a specific dosage form directly address

More information

6. In this temperature time graph for the heating of H 2O at a constant rate, the segment DE represents the

6. In this temperature time graph for the heating of H 2O at a constant rate, the segment DE represents the 1. Which of the following contains particles with the least freedom of motion? A) CO 2( ) B) HCl(aq) C) F 2(g) D) MgBr 2(s) E) C 6H 12O 6(aq) 2. During boiling, the temperature of a pure liquid substance

More information

DRY COATING : Techniques & Potentials

DRY COATING : Techniques & Potentials Water in Food Workshop Lausanne 2004 DRY COATING : Techniques & Potentials E. TEUNOU - E. IVANOVA - D. PONCELET Nantes Département du Génie des Procédés Alimentaire Content Who are we? Importance and Functionality

More information

IIS INNOVATIVE INJECTION SYSTEMS NEW PERSPECTIVES, MORE POSSIBILITIES

IIS INNOVATIVE INJECTION SYSTEMS NEW PERSPECTIVES, MORE POSSIBILITIES IIS INNOVATIVE INJECTION SYSTEMS NEW PERSPECTIVES, MORE POSSIBILITIES IIS REVOLUTIONARY ADMINISTRATION TECHNIQUES MORE EFFICIENCY AND SAFETY IIS researches and develops innovative injection systems. Within

More information

Recombinant, Insect Cell-Derived RSV Nanoparticle Vaccine

Recombinant, Insect Cell-Derived RSV Nanoparticle Vaccine Recombinant, Insect Cell-Derived RSV Nanoparticle Vaccine Gregory Glenn Chief Medical Officer MVADS-Copenhagen 4 July 2012 1 Agenda for RSV Discussion Overview of Insect Cell Technology Respiratory Syncytial

More information

DESIGN AND ENGINEERING OF INJECTABLE MICROPARTICLES FOR SUSTAINED RELEASE OF THERAPEUTIC PROTEINS USING A SUPERCRITICAL FLUID COATING PROCESS

DESIGN AND ENGINEERING OF INJECTABLE MICROPARTICLES FOR SUSTAINED RELEASE OF THERAPEUTIC PROTEINS USING A SUPERCRITICAL FLUID COATING PROCESS DESIGN AND ENGINEERING OF INJECTABLE MICROPARTICLES FOR SUSTAINED RELEASE OF THERAPEUTIC PROTEINS USING A SUPERCRITICAL FLUID COATING PROCESS F.S. Deschamps 1, A.M. DeConti 2, O. Thomas 1, R. Aubreton

More information

Guidelines for Pharmaceutical Equivalence Requirements

Guidelines for Pharmaceutical Equivalence Requirements Guidelines for Pharmaceutical Equivalence Requirements Version 1.1 1 September 2010 Page 1 of 9 Guidelines for Pharmaceutical Equivalence Requirements Version 1.1 Drug Sector Saudi Food & Drug Authority

More information

FOOD AND DRUGS AUTHORITY

FOOD AND DRUGS AUTHORITY G H A N A FOOD AND DRUGS AUTHORITY GUIDELINES FOR STABILITY TESTING OF ACTIVE PHARMACEUTICAL INGREDIENTS AND FINISHED PHARMACEUTICAL PRODUCTS Document No: FDA/DRI/DER/GL-STP/2013/07 Date of First Adoption:

More information

Lichenase fusions improve immunological properties of antigens

Lichenase fusions improve immunological properties of antigens Lichenase fusions improve immunological properties of antigens Konstantin Musiychuk Center for Molecular Biotechnology, Fraunhofer USA 03/27/2012 Lichenase Hydrolysis site of β-glycans Structure of the

More information

BioConvergence Technical Paper

BioConvergence Technical Paper BioConvergence Technical Paper # 2012001 Application of Thermal Analysis in Lyophilization Development and Optimization Kara Strass* and Kelly L. Zaleski, Ph.D.* *BioConvergence LLC, 4320 West Zenith Drive,

More information

Formulation Development & CTM Manufacturing Services

Formulation Development & CTM Manufacturing Services Formulation Development & CTM Manufacturing Services VxP Pharma Purdue Research Park 5225 Exploration Drive Indianapolis, IN 46241 Tel: 317.759.2299 Fax: 317.713.2950 VxP Pharmaprovides an extensive range

More information

Flock House virus VLPs as a tool in structure-based vaccine design. Malaria VLP Development Workshop September 23, 2009

Flock House virus VLPs as a tool in structure-based vaccine design. Malaria VLP Development Workshop September 23, 2009 Flock House virus VLPs as a tool in structure-based vaccine design Malaria VLP Development Workshop September 23, 2009 Flock House virus X-ray structure solved at 2.8 Å resolution Particle diameter 35

More information

Soluplus. Technical Information. October _090801e-01/Page 1 of 8. = Registered trademark of BASF group. Pharma Ingredients & Services

Soluplus. Technical Information. October _090801e-01/Page 1 of 8. = Registered trademark of BASF group. Pharma Ingredients & Services Technical Information Soluplus October 2009 03_090801e-01/Page 1 of 8 = Registered trademark of BASF group Pharma Ingredients & Services 03_090801e-01 October 2009 Page 2 of 8 Soluplus 1. Introduction

More information

Supercritical Fluid (SCF) Drying of Pharmaceuticals Peter York Chief Scientist, CrystecPharma

Supercritical Fluid (SCF) Drying of Pharmaceuticals Peter York Chief Scientist, CrystecPharma Supercritical Fluid (SCF) Drying of Pharmaceuticals Peter York Chief Scientist, CrystecPharma APS Focus Group Meeting, Loughborough 28 th January 2015 Presentation overview Introduction to SCF technologies

More information

Research Article Pharmaceutical Sciences

Research Article Pharmaceutical Sciences Page185 Research Article Pharmaceutical Sciences ENHANCEMENT OF DISSOLUTION RATE OF EFAVIRENZ BY SOLID DISPERSION TECHNIQUE B. Venkateswara Reddy 1*, K.V. Ramana Murthy 2 1* Department of Pharmaceutics,

More information

Extractables & Leachables. Ophthalmic Drug Products: A Regulatory Perspective Current Industry Challenges and Case Studies

Extractables & Leachables. Ophthalmic Drug Products: A Regulatory Perspective Current Industry Challenges and Case Studies Extractables & Leachables Ophthalmic Drug Products: A Regulatory Perspective Current Industry Challenges and Case Studies Ph.D. Pfizer Global Research and Development Bethesda 23/02/2011 Thresholds and

More information

We Care for Proteins Stabilization and Protection of Biopharmaceuticals, Vaccines and Biologic-Device Combination Products

We Care for Proteins Stabilization and Protection of Biopharmaceuticals, Vaccines and Biologic-Device Combination Products We Care for Proteins Stabilization and Protection of Biopharmaceuticals, Vaccines and Biologic-Device Combination Products Munich, June 2013 LEUKOCARE AG Established 2003 Owner Management and Private Investors

More information

Custom Antibodies Services. GeneCust Europe. GeneCust Europe

Custom Antibodies Services. GeneCust Europe. GeneCust Europe GeneCust Europe Laboratoire de Biotechnologie du Luxembourg S.A. 2 route de Remich L-5690 Ellange Luxembourg Tél. : +352 27620411 Fax : +352 27620412 Email : info@genecust.com Web : www.genecust.com Custom

More information

Spray-drying Biotherapeutics

Spray-drying Biotherapeutics Spray-drying Biotherapeutics Richard Kaye Investigator Product Development GSK R&D APS Freeze Drying and Alternative Drying Technologies for Parenterals Burleigh Court, Loughborough 28th January 2015 Contents

More information

SUSTAINED RELEASE From Coated Ion Exchange Resins. H.S. Hall Coating Place, Inc. Verona, WI 53593

SUSTAINED RELEASE From Coated Ion Exchange Resins. H.S. Hall Coating Place, Inc. Verona, WI 53593 SUSTAINED RELEASE From Coated Ion Exchange Resins 79-1 by H.S. Hall Coating Place, Inc. Verona, WI 53593 A substantial amount of work has been published concerning the use of ion exchange resins for sustained

More information

Experimental design on product development

Experimental design on product development Experimental design on product development Introduction What is the traditional developing method? What is experimental design? What do we need and what kind of possibilities do we have for designing?

More information

Applications of self-assembling peptides in controlled drug delivery

Applications of self-assembling peptides in controlled drug delivery Applications of self-assembling peptides in controlled drug delivery Sotirios Koutsopoulos, Ph.D. Problems associated with drug administration Drug concentration in blood C toxic C effective Time 1 The

More information

Pharmaceutical Sciences

Pharmaceutical Sciences SRI International Biosciences From Idea to IND Research on Disease Mechanisms Drug Discovery Drug Metabolism, Pharmacokinetics, & Toxicology Services Pharmaceutical Sciences Preclinical Development Planning

More information

CONSIDERATIONS FOR DEVELOPMENT OF A LYOPHILIZED BIOSIMILAR

CONSIDERATIONS FOR DEVELOPMENT OF A LYOPHILIZED BIOSIMILAR CONSIDERATIONS FOR DEVELOPMENT OF A LYOPHILIZED BIOSIMILAR A Case Study The patents for a number of parental biologic formulations are destined to expire in the United States between 2016 and 2027. Some

More information

Immunofluorescence and phalloidin labeling of mammalian cells

Immunofluorescence and phalloidin labeling of mammalian cells Immunofluorescence and phalloidin labeling of mammalian cells 2 Contents Materials for immunofluorescence and phalloidin labeling of mammalian cells...1 Immunofluorescence-labelling on cultivated adherent

More information

Evaluation of Clindamycin encapsulated in PLA/PLGA nanoparticles

Evaluation of Clindamycin encapsulated in PLA/PLGA nanoparticles Evaluation of Clindamycin encapsulated in PLA/PLGA nanoparticles Presented by Dr. Bismita Nayak bismita.nayak@gmail.com, nayakb@nitrkl.ac.in Department of Life science National Institute of Technology

More information

Pharma Ingredients & Services. Kollicoat IR White. Technical Information

Pharma Ingredients & Services. Kollicoat IR White. Technical Information Technical Information Kollicoat IR White August 2008 Supersedes issue dated June 2008 EMP 040901e-10/Page 1 of 12 = Registered trademark of BASF SE Ready-to-use coating for instant-release dosage forms

More information

Orodispersible drug delivery systems

Orodispersible drug delivery systems Orodispersible drug delivery systems Orodispersible drug delivery systems Disintegrate and/or dissolve rapidly in the saliva without the need for water. Tablets Films Fast-dissolving tablets are designed

More information

Higher Order mab Aggregate Analysis using New Innovative SEC Technology

Higher Order mab Aggregate Analysis using New Innovative SEC Technology Higher Order mab Aggregate Analysis using New Innovative SEC Technology Ronald E. Majors, Ph.D. LCGC No. America West Chester, PA USA WCBP 2016 Washington, DC Linda Lloyd, Ph.D. Agilent Technologies Church

More information

WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products

WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of these guidelines 1.2 Scope of these guidelines 1.3 General principles

More information

Supplementary Figure 1.

Supplementary Figure 1. Supplementary Figure 1. Assessment of quaternary structure of soluble RSV F proteins. Soluble variants of F proteins from A2 and B1 RSV strains were expressed in HEK293 cells. The cell culture supernatants

More information

Injection Moulding as a One-Stop-Production to Produce Pharmaceutical Dosage Forms

Injection Moulding as a One-Stop-Production to Produce Pharmaceutical Dosage Forms Injection Moulding as a One-Stop-Production to Produce Pharmaceutical Dosage Forms Karin Eggenreich, Simone Schrank, Gerold Koscher, Daniel Treffer, Eva Roblegg and Johannes G. Khinast K1 Competence Center

More information

Computation of Solubility parameters using Molecular. dynamics simulation

Computation of Solubility parameters using Molecular. dynamics simulation Appendix I Appendix I Computation of Solubility parameters using Molecular dynamics simulation Computational Methods Molecular dynamics (MD) simulations were carried out using the Accelrys Materials Studio[1]

More information

Pharmaceutical Development for ADCs: Not as Simple as ABC

Pharmaceutical Development for ADCs: Not as Simple as ABC Pharmaceutical Development for ADCs: Not as Simple as ABC Pharmaceutical Development for ADCs Formulation, process, and analytical development for antibody-drug conjugates, or ADCs, is complex. While the

More information

METHODS IN CELL BIOLOGY EXAM II, MARCH 26, 2008

METHODS IN CELL BIOLOGY EXAM II, MARCH 26, 2008 NAME KEY METHODS IN CELL BIOLOGY EXAM II, MARCH 26, 2008 1. DEFINITIONS (30 points). Briefly (1-3 sentences, phrases, word, etc.) define the following terms or answer question. A. depot effect refers to

More information

The 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability. WHO Biowaiver Guideline in Regulatory Practice

The 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability. WHO Biowaiver Guideline in Regulatory Practice The 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability WHO Biowaiver Guideline in Regulatory Practice Dr Kamel IDDIR General Director Medicines and Pharmacy Directorate Berne

More information

GENERAL PHARMACOPOEIA MONOGRAPH

GENERAL PHARMACOPOEIA MONOGRAPH MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION GENERAL PHARMACOPOEIA MONOGRAPH Immunobiological GPM. 1.8.1.0002.15 medicinal products First Edition The present General Pharmacopoeia Monograph applies to

More information

nanoprecipitation mpeg-pla 2 nd Emulsion mpeg-pla in DCM

nanoprecipitation mpeg-pla 2 nd Emulsion mpeg-pla in DCM THERAPEUTIC NANOTECHNOLOGY LAB MODULE Location: BioNano Lab, 3119 Micro and Nanotechnology Laboratory (MNTL) Instructor: Jianjun Cheng, Assistant Professor of Materials Science and Engineering Lab Assistants:

More information

We make drugs smarter

We make drugs smarter We make drugs smarter Brookwood Pharmaceutical Services WE MAKE DRUGS SMARTER Using our 40 years of experience, our state of the art facilities and our IP protected technologies, we leverage existing capabilities

More information

The Role of Compounded Medicines in Therapy. Loyd V. Allen, Jr., Ph.D.,R.Ph. Editor-in International Journal of Pharmaceutical Compounding

The Role of Compounded Medicines in Therapy. Loyd V. Allen, Jr., Ph.D.,R.Ph. Editor-in International Journal of Pharmaceutical Compounding The Role of Compounded Medicines in Therapy Loyd V. Allen, Jr., Ph.D.,R.Ph. Editor-in in-chief International Journal of Pharmaceutical Compounding Contact Information www.ijpc.com Lallen@ijpc.com 122 N.

More information

Mag4C-Lv Kit - Results

Mag4C-Lv Kit - Results Mag4C-Lv Kit - Results Mag4C-Lv Kit Magnetic capture for viral concentration & storage buffer for superior viral preservation OZ Biosciences is delighted to announce the launching of a new product Mag4C-Lv

More information

Freeze Granulation for Processing of Nano Materials. Kent Rundgren, President of PowderPro AB

Freeze Granulation for Processing of Nano Materials. Kent Rundgren, President of PowderPro AB Freeze Granulation for Processing of Nano Materials Kent Rundgren, President of PowderPro AB Freeze Granulation Process Suspension Spray freezing Air Freeze drying Vacuum Atomisation Sublimation Instant

More information

HIGH PRESSURE MICRONISATION OF POLYMERS

HIGH PRESSURE MICRONISATION OF POLYMERS HIGH PRESSURE MICRONISATION OF POLYMERS Željko Knez University of Maribor, Faculty of Chemistry and Chemical Engineering, Smetanova 17, SI-2000 Maribor, Slovenia Fax: +386 2 25 16 750, e-mail: zeljko.knez@uni-mb.si

More information

Bean common mosaic virus (BCMV) ELISA Kit

Bean common mosaic virus (BCMV) ELISA Kit Bean common mosaic virus (BCMV) ELISA Kit Cat.No: DEIAPV17 Lot. No. (See product label) Size 5000T Intended use The test can be used to detect BCMV in infected host plants. General Description Bean common

More information

Evonik Birmingham Laboratories

Evonik Birmingham Laboratories Evonik Birmingham Laboratories An integrated CDMO for advanced parenterals with a portfolio of delivery technologies, formulation development services and GMP manufacturing Evonik Birmingham Laboratories

More information

Dr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur

Dr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur Dr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur GMP ( Adopted in 1975 ) In India Good manufacturing practices are the practices required in order to conform to guidelines recommended

More information

Handbook Controlled Release Of Drugs Polymers And Aggregate Systems

Handbook Controlled Release Of Drugs Polymers And Aggregate Systems Handbook Controlled Release Of Drugs Polymers And Aggregate Systems (1) The development of controlled release drug delivery system has long been a major area of bipinnata, which is used as release retardant

More information

Using the Sartobind pico

Using the Sartobind pico Using the Sartobind pico Optimizing Steps for using micro-scale membrane adsorbers on liquid chromatography systems Application Note Steps for the successful use of Sartobind pico 1. Start with a new unused

More information

Anti-Tilapia (Oreochromis niloticus) IgM monoclonal antibody. Product no: F04

Anti-Tilapia (Oreochromis niloticus) IgM monoclonal antibody. Product no: F04 Anti-Tilapia (Oreochromis niloticus) IgM monoclonal antibody Product no: F04 Product Description This monoclonal antibody (Mab) reacts with Anti-Tilapia (Oreochromis niloticus) immunoglobulin M (IgM).

More information

INTRODUCTION TO INDUSTRIAL PHARMACY LAB 1

INTRODUCTION TO INDUSTRIAL PHARMACY LAB 1 INTRODUCTION TO INDUSTRIAL PHARMACY LAB 1 LAB INSTRUCTORS: LECT. ANAS T ARIK NAFEA ASSIST. LECT. ZAINAB HASSAN MAHDI Definition of Industrial Pharmacy The conversion of raw materials into certain dosage

More information

PQRI Research Project Proposal: Reporting and Qualification Thresholds for Leachables in Parenteral and Ophthalmic Drug Products

PQRI Research Project Proposal: Reporting and Qualification Thresholds for Leachables in Parenteral and Ophthalmic Drug Products PQRI Research Project Proposal: Reporting and Qualification Thresholds for Leachables in Parenteral and Ophthalmic Drug Products Prepared by: Doug Ball (Pfizer), Diane Paskiet (West-Monarch), Daniel L.

More information

Physical pharmacy. dr basam al zayady

Physical pharmacy. dr basam al zayady Physical pharmacy Lec 5 dr basam al zayady Liquefaction of Gases: When a gas is cooled, it loses some of its kinetic energy in the form of heat, and the velocity of the molecules decreases. If pressure

More information

Chapter 9 Controlling Microbial Growth in the Environment. 10/1/ MDufilho

Chapter 9 Controlling Microbial Growth in the Environment. 10/1/ MDufilho Chapter 9 Controlling Microbial Growth in the Environment 10/1/2017 1 MDufilho Table 91 Terminology of Microbial Control 10/1/2017 MDufilho 2 Number of living microbes Figure 91 A plot of microbial death

More information

Sera-Mag SpeedBeads Magnetic Protein A/G Particles

Sera-Mag SpeedBeads Magnetic Protein A/G Particles Procedure 29-1079-14 AA Protein enrichment Sera-Mag SpeedBeads Magnetic Protein A/G Particles Sera-Mag SpeedBeads Protein A/G Magnetic Particles (Table 1) provide a fast and convenient method for both

More information

International Journal of Pharma and Bio Sciences

International Journal of Pharma and Bio Sciences S. HONARY 1, P. EBRAHIMI 2 AND N. EMRANI 1 1 Mazandaran University of Medical Sciences, School of Pharmacy, Phrmaceutical Research Center, Sari, Iran 2 Gonbad Institute of Higher Education, P. O. Box 163,

More information

Protein A Agarose Immunoprecipitation Kit

Protein A Agarose Immunoprecipitation Kit Protein A Agarose Immunoprecipitation Kit Catalog Number KA0568 20 Reactions Version: 01 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 General Information...

More information

EZ-10 SPIN COLUMN GENOMIC DNA MINIPREPS KIT HANDBOOK

EZ-10 SPIN COLUMN GENOMIC DNA MINIPREPS KIT HANDBOOK EZ-0 SPIN COLUMN GENOMIC DNA MINIPREPS KIT HANDBOOK (Bacteria, Plant, Animal, Blood) Version 8 Rev 05/0/03 EZ-0 Genomic DNA Kit Handbook Table of Contents Introduction Limitations of Use Features Applications

More information

CONTRACTING ORGANIZATION: Albert Einstein College of Medicine Bronx, NY 10461

CONTRACTING ORGANIZATION: Albert Einstein College of Medicine Bronx, NY 10461 AD Award Number: W81XWH-08-1-0011 TITLE: Defining B. Anthracis Protective Antigen Antigenic Domains PRINCIPAL INVESTIGATOR: Arturo Casadevall, M.D., Ph.D. CONTRACTING ORGANIZATION: Albert Einstein College

More information

METHOCEL. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow

METHOCEL. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow METHOCEL Cellulose Ethers A product that can do it all TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow The possibilities are endless Pharmaceutical companies are continuously

More information

Answer ALL questions. Use the answer grid provided for ALL of your answers. For each of the following questions there is ONE correct answer only.

Answer ALL questions. Use the answer grid provided for ALL of your answers. For each of the following questions there is ONE correct answer only. UNIVERSITY OF EAST ANGLIA School of Pharmacy Main Series UG Examination 2013-14 SPECIAL PAPER FOR: PHARMACEUTICAL TECHNOLOGY PHA-2FGY Time allowed: 2 hours Part ONE Answer ALL questions. Use the answer

More information

Dynamic High Capacity Mustang Q Membrane Units for Scaleable Anion Exchange Chromatography Purification of Adenoviral Vectors

Dynamic High Capacity Mustang Q Membrane Units for Scaleable Anion Exchange Chromatography Purification of Adenoviral Vectors Contact Us: www.pall.com/contact Dynamic High Capacity Mustang Q Membrane Units for Scaleable Anion Exchange Chromatography Purification of Adenoviral Vectors Dynamic High Capacity Mustang Q Membrane Units

More information

Design and Dosage Form. Dr. Deny Susanti

Design and Dosage Form. Dr. Deny Susanti Design and Dosage Form Dr. Deny Susanti Example 1 Aspirin tablet is stable but not as a liquid dosage form How to design liquid form? Soluble or dispersible aspirin tablets-to be dissolved in water Note:

More information

RapidChek SELECT Salmonella Enteritidis Test System

RapidChek SELECT Salmonella Enteritidis Test System RapidChek SELECT Salmonella Enteritidis Test System Part #: 7000220, 7000221, 7000222, 7000228 AOAC Approved Protocols: This test kit s performance was reviewed by AOAC Research Institute and was found

More information

Polymorph Screening Strategies and a Concomitant Polymorph Case Study

Polymorph Screening Strategies and a Concomitant Polymorph Case Study Polymorph Screening Strategies and a Concomitant Polymorph Case Study Aniruddh Andy Singh, Ph.D. Mahmoud Mirmehrabi, Ph.D., P.Eng. Johnson Matthey Pharma Services Chemical and Crystallization Research

More information

Leading Pharmaceutical Innovation

Leading Pharmaceutical Innovation Leading Pharmaceutical Innovation Hyaluronic Acid Experts Leading Pharmaceutical Innovation Altergon, born in 2000 in Morra de Sanctis (Avellino) represents a Centre of Excellence and Innovation for the

More information

Cat. No. MG17PG-1ml XPRESSAFFINITY PROTEIN G- MAGNETIC NANOPARTICLES (MNP) FOR RESEARCH APPLICATIONS

Cat. No. MG17PG-1ml XPRESSAFFINITY PROTEIN G- MAGNETIC NANOPARTICLES (MNP) FOR RESEARCH APPLICATIONS Cat. No. MG17PG-1ml XPRESSAFFINITY PROTEIN G- MAGNETIC NANOPARTICLES (MNP) FOR RESEARCH APPLICATIONS Product Description: MagGenome s Protein G-MNP provides a fast and convenient method for affinity based

More information

Transdermal Drug Delivery System Regulatory Requirements (USA)

Transdermal Drug Delivery System Regulatory Requirements (USA) Transdermal Drug Delivery System Regulatory Requirements (USA) Vinod P. Shah, Ph. D., FIP Scientific Secretary Conference on To and Thru the Skin IPA AAPS FIP - APSTJ Mumbai, India, February 20-21, 2009

More information

Product Permission Document (PPD) of Typhoid Polysaccharide Vaccine I.P. (Brand Name Bio-Typh TM )

Product Permission Document (PPD) of Typhoid Polysaccharide Vaccine I.P. (Brand Name Bio-Typh TM ) 1 Product Permission Document (PPD) of Typhoid Polysaccharide Vaccine I.P. (Brand Name Bio-Typh TM ) 1. Introduction Typhoid Polysaccharide Vaccine is a preparation of purified Vi capsular polysaccharide

More information

Scalable Strategies for Parenteral Dosage Form Selection

Scalable Strategies for Parenteral Dosage Form Selection Scalable Strategies for Parenteral Dosage Form Selection Tony Pidgeon Process Technology Director Pharma Services Patheon, part of Thermo Fisher Scientific There are many parenteral dosage forms from which

More information

: Scientific research and development,use as laboratory reagent,manufacture of substances

: Scientific research and development,use as laboratory reagent,manufacture of substances SECTION 1: Identification 1.1. Identification Product form Poly(ethylene glycol), MW 400 (PEG 400) Date of issue: 11/21/2017 Revision date: 11/21/2017 Supersedes: 11/15/2013 Version: 2.0 : Substance Substance

More information

Genomic DNA Mini Kit (Blood/Cultured Cell) For research use only

Genomic DNA Mini Kit (Blood/Cultured Cell) For research use only Genomic DNA Mini Kit (Blood/Cultured Cell) For research use only Sample : up to 300 µl of whole blood, up to 200 µl of frozen blood, up to 200 µl of buffy coat, cultured animal cells (up to 1 x 107), 9

More information

HELENA LABORATORIES 1530 Lindbergh Dr. / P.O. Box 752 Beaumont, TX USA Toll Free

HELENA LABORATORIES 1530 Lindbergh Dr. / P.O. Box 752 Beaumont, TX USA Toll Free SDS: 3040 Page 1 of 8 SAFETY DATA SHEET HELENA LABORATORIES 1530 Lindbergh Dr. / P.O. Box 752 Beaumont, TX 77704 0752 USA Toll Free 800 231 5663 DATE PREPARED: 6/7/2017 REVISION: 2 1. IDENTIFICATION Product

More information

PD-1 [Biotinylated] : PD-L1 Inhibitor Screening ELISA Assay Pair

PD-1 [Biotinylated] : PD-L1 Inhibitor Screening ELISA Assay Pair PD-1 [Biotinylated] : PD-L1 Inhibitor Screening ELISA Assay Pair Pack Size: 96 tests / 480 tests Catalog Number:EP-101 IMPORTANT: Please carefully read this manual before performing your experiment. For

More information

Material Safety Data Sheet

Material Safety Data Sheet Material Safety Data Sheet 28 Jan 2012 Version 1.0 Material Safety Data Sheet Human Serum Albumin (HSA 10% Solution). Section 1 - Product and Company Identification 1.1 Product Name: Human Serum Albumin

More information

White Paper. Advancing the Understanding of Emulsions in Food Products Using State of the Art Microscopy. Haixia Xu Scientist, Microscopy

White Paper. Advancing the Understanding of Emulsions in Food Products Using State of the Art Microscopy. Haixia Xu Scientist, Microscopy White Paper Advancing the Understanding of Emulsions in Food Products Using Haixia Xu Scientist, Microscopy Introduction The importance of understanding food microstructure should not be underestimated.

More information

Soil DNA Extraction Kit

Soil DNA Extraction Kit Instruction Manual Ver. 09.23.16 For Research Use Only Soil DNA Extraction Kit Advantages IB47800 (4 Preparation Sample Kit) IB47801 (50 Preparation Kit) IB47802 (100 Preparation Kit) Sample: 250-500 mg

More information

Presto 96 Well gdna Bacteria Kit

Presto 96 Well gdna Bacteria Kit Presto 96 Well gdna Bacteria Kit 96GBB02 (2 x 96 well plates/kit) 96GBB04 (4 x 96 well plates/kit) 96GBB10 (10 x 96 well plates/kit) Instruction Manual Ver. 05.04.17 For Research Use Only Advantages Sample:

More information

Mucosal Immunity induced by VLPs

Mucosal Immunity induced by VLPs Virus-like paticles (VLPs) as vaccines, vectors and adjuvants, Fondation Mérieux, Annecy, 04 Mucosal Immunity induced by VLPs Denise Nardelli-Haefliger Lausanne University Hospital, Switzerland Purified

More information

Regulatory Challenges for the Licensure of Future Vaccines

Regulatory Challenges for the Licensure of Future Vaccines Regulatory Challenges for the Licensure of Future Vaccines Tong Wu, Ph.D. Bacterial & Combination Vaccine Division, BGTD, Health Canada June 26-29, 2018, Seoul, Korea, the Global Bio Conference 1 Disclaimer

More information

Vaccine Cuisine EDIBLE VACCINES. Nina Gloriani Barzaga, M.D.,Ph.D. University of the Philippines Manila

Vaccine Cuisine EDIBLE VACCINES. Nina Gloriani Barzaga, M.D.,Ph.D. University of the Philippines Manila Slide 1 Plant Made Pharmaceuticals EDIBLE VACCINES Vaccine Cuisine Nina Gloriani Barzaga, M.D.,Ph.D. University of the Philippines Manila 3 rd Asian Biotechnology Conference, Manila Nov 9-10, 2006 Slide

More information

Alternatives to In-Vivo Testing for Animal Biologics: North American Regulatory Perspective

Alternatives to In-Vivo Testing for Animal Biologics: North American Regulatory Perspective Alternatives to In-Vivo Testing for Animal Biologics: North American Regulatory Perspective Geetha B. Srinivas, DVM, PhD Section Leader, Virology Center for Veterinary Biologics USDA/APHIS/VS IABS 2018,

More information

A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Clostridium difficile

A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Clostridium difficile A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Clostridium difficile vaccine administered with or without Aluminum Hydroxide, in a 3-Dose Regimen in Healthy Adults Aged 50

More information

Approaches to the formulation of poorly soluble drugs

Approaches to the formulation of poorly soluble drugs 1 Approaches to the formulation of poorly soluble drugs R. Christian Moreton, Ph.D FinnBrit Consulting ExcipientFest 2013, April 30 May 01, 2013, Baltimore, MD 2 Disclaimer The views expressed in this

More information

OPTIMIZATION OF FORMULATION OF FAST DISSOLVING FILMS MADE OF PULLULAN POLYMER

OPTIMIZATION OF FORMULATION OF FAST DISSOLVING FILMS MADE OF PULLULAN POLYMER Research Article OPTIMIZATION OF FORMULATION OF FAST DISSOLVING FILMS MADE OF PULLULAN POLYMER Accepted on: 04-04-2011; Finalized on: 06-07-2011. ABSTRACT Seema Saini 1, Samta 1*, A. C. Rana 1, and Sumit

More information

VWR CO 2 RESISTANT TUBES

VWR CO 2 RESISTANT TUBES VWR CO 2 RESISTANT TUBES Protects Samples Shipped on Keeps ph Stable CO 2 Resistant Certified for Shipping VWR CO 2 VWR CO 2 Only VWR s CO 2 Resistant Tubes are designed to protect samples that are shipped

More information

High-throughput and Sensitive Size Exclusion Chromatography (SEC) of Biologics Using Agilent AdvanceBio SEC Columns

High-throughput and Sensitive Size Exclusion Chromatography (SEC) of Biologics Using Agilent AdvanceBio SEC Columns High-throughput and Sensitive Size Exclusion Chromatography (SEC) of Biologics Using Agilent AdvanceBio SEC Columns Agilent AdvanceBio SEC 3 Å, 2.7 µm columns Application note Bio-Pharmaceutical Author

More information

I Jornada: Oportunidades de negocio en nanotecnología

I Jornada: Oportunidades de negocio en nanotecnología I Jornada: Oportunidades de negocio en nanotecnología NanoBioTer Maximizing polymer potential through flexible nanotechnology Contents About Us Technology Selected Data Production process and Products

More information

DNA isolation from tissue DNA isolation from eukaryotic cells (max. 5 x 106 cells) DNA isolation from paraffin embedded tissue

DNA isolation from tissue DNA isolation from eukaryotic cells (max. 5 x 106 cells) DNA isolation from paraffin embedded tissue INDEX KIT COMPONENTS 3 STORAGE AND STABILITY 3 BINDING CAPACITY 3 INTRODUCTION 3 IMPORTANT NOTES 4 EUROGOLD TISSUE DNA MINI KIT PROTOCOLS 5 A. DNA isolation from tissue 5 B. DNA isolation from eukaryotic

More information